Skip to main content
Figure 3 | Journal of Hematology & Oncology

Figure 3

From: Administration of imatinib after allogeneic hematopoietic stem cell transplantation may improve disease-free survival for patients with Philadelphia chromosome-positive acute lymphobla stic leukemia

Figure 3

Overall survival (OS) at 5 years in imatinib and non-imatinib groups, post-HCT. Kaplan-Meier analysis showed that the 5-year OS of patients in the imatinib-group was significantly higher than the patients in the non-imatinib group (86.7% vs 34.3%, p = 0.000).

Back to article page

Journal of Hematology & Oncology

ISSN: 1756-8722

Contact us